Finding new treatments for T-Cell Acute Lymphoblastic Leukemia
Discovery of MAP2K7 Inhibitors Through DNA-Encoded Chemical Screens to Treat T-Cell Acute Lymphoblastic Leukemia
This study is looking for new treatments that can help kids and young adults with T-Cell Acute Lymphoblastic Leukemia by targeting a specific protein that makes some leukemia cells resistant to current therapies, aiming to improve their chances of recovery.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10947327 on NIH RePORTER |
What this research studies
This research focuses on developing new inhibitors for MAP2K7, a protein that plays a role in T-Cell Acute Lymphoblastic Leukemia (T-ALL). The study aims to identify effective therapies that can target drug-resistant leukemia cells, which are responsible for relapses in patients. By using advanced chemical screening techniques, researchers hope to discover compounds that can specifically inhibit MAP2K7 and improve treatment outcomes for patients with T-ALL. This approach is particularly important for children and young adults who are at a higher risk of treatment failure.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with T-Cell Acute Lymphoblastic Leukemia, especially those who have experienced treatment failure or relapse.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with T-Cell Acute Lymphoblastic Leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for T-ALL, potentially reducing relapse rates and improving survival outcomes for patients.
How similar studies have performed: While targeting MAP2K7 is a novel approach, previous research has shown promise in targeting similar pathways in leukemia treatment, indicating potential for success.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Lacorazza, Daniel — Baylor College of Medicine
- Study coordinator: Lacorazza, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.